These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 19903844)

  • 1. De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model.
    Watters JW; Cheng C; Majumder PK; Wang R; Yalavarthi S; Meeske C; Kong L; Sun W; Lin J; Heyer J; Ware C; Winter C; Reilly JF; Demuth T; Clark S; Chiu MI; Robinson MO; Kohl N; Kannan K
    Cancer Res; 2009 Dec; 69(23):8949-57. PubMed ID: 19903844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma.
    O'Rourke CJ; Matter MS; Nepal C; Caetano-Oliveira R; Ton PT; Factor VM; Andersen JB
    Hepatology; 2020 Jan; 71(1):196-213. PubMed ID: 31211856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.
    Abravanel DL; Belka GK; Pan TC; Pant DK; Collins MA; Sterner CJ; Chodosh LA
    J Clin Invest; 2015 Jun; 125(6):2484-96. PubMed ID: 25961456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HES6 promotes prostate cancer aggressiveness independently of Notch signalling.
    Carvalho FL; Marchionni L; Gupta A; Kummangal BA; Schaeffer EM; Ross AE; Berman DM
    J Cell Mol Med; 2015 Jul; 19(7):1624-36. PubMed ID: 25864518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy.
    Zhou Y; Rideout WM; Bressel A; Yalavarthi S; Zi T; Potz D; Farlow S; Brodeur J; Monti A; Reddipalli S; Xiao Q; Bottega S; Feng B; Chiu MI; Bosenberg M; Heyer J
    PLoS One; 2014; 9(8):e105886. PubMed ID: 25162504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting γ-secretase in breast cancer.
    Han J; Shen Q
    Breast Cancer (Dove Med Press); 2012 Jun; 4():83-90. PubMed ID: 24367196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerating cancer modeling with RNAi and nongermline genetically engineered mouse models.
    Livshits G; Lowe SW
    Cold Spring Harb Protoc; 2013 Nov; 2013(11):. PubMed ID: 24184755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. γ-Secretase inhibitors and modulators.
    Golde TE; Koo EH; Felsenstein KM; Osborne BA; Miele L
    Biochim Biophys Acta; 2013 Dec; 1828(12):2898-907. PubMed ID: 23791707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.
    Chu Q; Orr BA; Semenkow S; Bar EE; Eberhart CG
    Clin Cancer Res; 2013 Jun; 19(12):3224-33. PubMed ID: 23630166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.
    Magnani L; Stoeck A; Zhang X; Lánczky A; Mirabella AC; Wang TL; Gyorffy B; Lupien M
    Proc Natl Acad Sci U S A; 2013 Apr; 110(16):E1490-9. PubMed ID: 23576735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Notch inhibition with current therapies for breast cancer treatment.
    Brennan K; Clarke RB
    Ther Adv Med Oncol; 2013 Jan; 5(1):17-24. PubMed ID: 23323144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.
    Ramakrishnan V; Ansell S; Haug J; Grote D; Kimlinger T; Stenson M; Timm M; Wellik L; Halling T; Rajkumar SV; Kumar S
    Leukemia; 2012 Feb; 26(2):340-8. PubMed ID: 21826062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.
    O'Hagan RC; Heyer J
    Genes Cancer; 2011 Mar; 2(3):335-43. PubMed ID: 21779503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models.
    Huijbers IJ; Krimpenfort P; Berns A; Jonkers J
    Bioessays; 2011 Sep; 33(9):701-10. PubMed ID: 21735458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
    Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
    Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repression of mammary stem/progenitor cells by p53 is mediated by Notch and separable from apoptotic activity.
    Tao L; Roberts AL; Dunphy KA; Bigelow C; Yan H; Jerry DJ
    Stem Cells; 2011 Jan; 29(1):119-27. PubMed ID: 21280161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Notch and its oncogenic signaling crosstalk in breast cancer.
    Guo S; Liu M; Gonzalez-Perez RR
    Biochim Biophys Acta; 2011 Apr; 1815(2):197-213. PubMed ID: 21193018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-germline genetically engineered mouse models for translational cancer research.
    Heyer J; Kwong LN; Lowe SW; Chin L
    Nat Rev Cancer; 2010 Jul; 10(7):470-80. PubMed ID: 20574449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Notch to target cancer stem cells.
    Pannuti A; Foreman K; Rizzo P; Osipo C; Golde T; Osborne B; Miele L
    Clin Cancer Res; 2010 Jun; 16(12):3141-52. PubMed ID: 20530696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.